+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast to 2030- Product Image
Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast to 2030- Product Image
Sale

Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925117
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The multicancer screening market is emerging as a pivotal force in early cancer diagnostics, offering healthcare stakeholders an integrated approach to detect multiple cancer types efficiently. As technological and regulatory advancements converge, industry leaders and decision-makers are navigating an evolving competitive landscape defined by innovation, changing reimbursement models, and global shifts in healthcare policy.

Market Snapshot: Multicancer Screening Market

The Multicancer Screening Market grew from USD 1.53 billion in 2024 to USD 1.67 billion in 2025. It is expected to continue growing at a CAGR of 10.05%, reaching USD 2.72 billion by 2030. This robust expansion is fueled by new diagnostic technologies, expanding clinical demand, and increasing emphasis on proactive healthcare. The adoption of multicancer screening is accelerating as key markets respond to the rising prevalence of cancer and evolving payer and regulatory landscapes.

Scope & Segmentation

This report delivers a comprehensive breakdown of the multicancer screening market by segment, technology, funding model, application, end user, and regional coverage. The analysis provides strategic segmentation insights to support informed decision-making across operational and commercial functions.

  • Test Types: Gene panel assays, laboratory developed tests, liquid biopsy.
  • Cancer Types: Breast, colorectal, leukemia, lung, non-specific multi-organ, prostate.
  • Technologies: Mass spectrometry, microarray, next-generation sequencing, polymerase chain reaction.
  • Payment Sources: Government subsidies, out-of-pocket payment, private health insurance.
  • Applications: Diagnostic screening (early detection, risk assessment), prognostics (patient monitoring, therapy selection, treatment efficacy assessment), research (biomarker discovery, genetic research).
  • End Users: Ambulatory surgical centers, diagnostic centers, hospitals, research institutions, specialty clinics.
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (key markets include United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: ANPAC Bio-Medical Science, Burning Rock Biotech, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Elypta, EpiCypher, Epigenomics AG, Exact Sciences, Foundation Medicine, Freenome, Fulgent Genetics, Gene Solutions, Grail/Illumina, Guangzhou AnchorDx, Guardant Health, Invitae, LabCorp, Lucence, Micronoma, MiRXES, Myriad Genetics, Natera, Naveris, NeoGenomics, OneTest, Siemens Healthineers, StageZero Life Sciences.

Key Takeaways for Decision-Makers

  • Multicancer screening leverages genomic and proteomic innovations, enabling earlier intervention and improved clinical outcomes over conventional single-cancer tests.
  • Stakeholders must manage regulatory complexity and rapidly evolving reimbursement environments, requiring adaptable commercialization strategies.
  • Collaborations between diagnostics companies, academic institutions, and payers are shaping the ecosystem and accelerating innovation cycles.
  • Tailored solutions addressing segment-specific needs are essential for market penetration, as no universal approach dominates all indications or settings.
  • Investment in supply chain resilience is becoming increasingly critical, particularly in light of tariff-related cost pressures impacting device and reagent availability.
  • Emerging regions demonstrate untapped growth potential, but localized strategies are essential to overcome infrastructure and funding constraints.

Tariff Impact

New tariffs introduced in 2025 are presenting cost and procurement challenges, particularly affecting laboratories dependent on imported reagents and sequencing equipment. Market participants are responding with localized production, alternative sourcing, and proactive engagements with regulators to maintain business continuity and mitigate additional costs. Payers are reassessing reimbursement models in response to these operational shifts and to ensure continued patient access to screening.

Methodology & Data Sources

This market research integrates primary interviews with industry leaders, laboratory managers, and payers, augmented by in-depth site visits. Extensive secondary research, including peer-reviewed publications, regulatory filings, and corporate reports, supports robust data triangulation and outcome validation.

Why This Report Matters

  • Supports informed investment, partnering, and procurement decisions based on segmented, actionable insights across geographies and technologies.
  • Equips leadership teams with up-to-date intelligence on market drivers, risk factors, and adoption trends to optimize commercial strategy.
  • Enables benchmarking of competitors and identification of new market entry or partnership opportunities within the multicancer screening ecosystem.

Conclusion

The multicancer screening market is poised for continued transformation as technological advances and market dynamics converge. Organizations that prioritize resilience, build strategic partnerships, and tailor offerings to diverse clinical and regional needs will lead future directions in cancer diagnostics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multicancer Screening Market, by Test Type
8.1. Introduction
8.2. Gene Panel
8.3. Laboratory Developed Test
8.4. Liquid Biopsy
9. Multicancer Screening Market, by Cancer Type
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Leukemia
9.5. Lung Cancer
9.6. Non-Specific Multi-Organ Cancer
9.7. Prostate Cancer
10. Multicancer Screening Market, by Technology
10.1. Introduction
10.2. Mass Spectrometry
10.3. Microarray
10.4. Next - Generation Sequencing
10.5. Polymerase Chain Reaction
11. Multicancer Screening Market, by Payment Source
11.1. Introduction
11.2. Government Subsidies
11.3. Out-of-Pocket Payment
11.4. Private Health Insurance
12. Multicancer Screening Market, by Application
12.1. Introduction
12.2. Diagnostic Screening
12.2.1. Early Detection
12.2.2. Risk Assessment
12.3. Prognostics
12.3.1. Patient Monitoring
12.3.2. Therapy Selection
12.3.3. Treatment Efficacy Assessment
12.4. Research Applications
12.4.1. Biomarker Discovery
12.4.2. Genetic Research
13. Multicancer Screening Market, by End User
13.1. Introduction
13.2. Ambulatory Surgical Centers
13.3. Diagnostic Centers
13.4. Hospitals
13.5. Research Institutions
13.6. Specialty Clinics
14. Americas Multicancer Screening Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Multicancer Screening Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Multicancer Screening Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. ANPAC Bio-Medical Science Co., Ltd.
17.3.2. Burning Rock Biotech Limited
17.3.3. Caris Life Sciences
17.3.4. Coyne Medical Ltd.
17.3.5. Delfi Diagnostics, Inc.
17.3.6. Elypta AB
17.3.7. EpiCypher, Inc.
17.3.8. Epigenomics AG
17.3.9. Exact Sciences Corporation
17.3.10. Foundation Medicine, Inc.
17.3.11. Freenome Holdings, Inc.
17.3.12. Fulgent Genetics, Inc.
17.3.13. Gene Solutions
17.3.14. Grail, LLC by Illumina, Inc.
17.3.15. Guangzhou AnchorDx Medical Co., Ltd.
17.3.16. Guardant Health, Inc.
17.3.17. Invitae Corporation
17.3.18. Laboratory Corporation of America Holdings
17.3.19. Lucence Health Inc.
17.3.20. Micronoma, Inc.
17.3.21. MiRXES Pte Ltd.
17.3.22. Myriad Genetics, Inc.
17.3.23. Natera, Inc.
17.3.24. Naveris, Inc.
17.3.25. NeoGenomics Laboratories
17.3.26. OneTest
17.3.27. Siemens Healthineers AG
17.3.28. StageZero Life Sciences. Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. MULTICANCER SCREENING MARKET MULTI-CURRENCY
FIGURE 2. MULTICANCER SCREENING MARKET MULTI-LANGUAGE
FIGURE 3. MULTICANCER SCREENING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. CANADA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 70. CANADA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 72. CANADA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 73. CANADA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 74. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 81. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 127. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 128. GERMANY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 132. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 134. FRANCE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. FRANCE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 136. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 137. FRANCE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 138. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 149. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 150. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. ITALY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 152. ITALY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. ITALY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 154. ITALY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 155. ITALY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 156. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 159. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. SPAIN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 161. SPAIN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. SPAIN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 163. SPAIN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 164. SPAIN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 165. SPAIN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 195. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 196. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 197. DENMARK MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. DENMARK MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 199. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 200. DENMARK MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 201. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 213. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. QATAR MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 215. QATAR MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. QATAR MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 217. QATAR MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 218. QATAR MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 219. QATAR MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 222. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 224. FINLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. FINLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 226. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 227. FINLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 228. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 249. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 251. EGYPT MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. EGYPT MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 253. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 254. EGYPT MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 255. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 258. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. TURKEY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 260. TURKEY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. TURKEY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 262. TURKEY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 263. TURKEY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 264. TURKEY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 276. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 278. NORWAY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. NORWAY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 280. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 281. NORWAY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 282. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 285. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 286. POLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 287. POLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. POLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 289. POLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 290. POLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 291. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 311. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 312. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 313. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. CHINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 315. CHINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 316. CHINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 317. CHINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 318. CHINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 319. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 321. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 322. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 323. INDIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 324. INDIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 325. INDIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 326. INDIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
TABLE 327. INDIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 328. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 330. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 331. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 332. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
TABLE 333. JAPAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 334. JAPAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
TABLE 335. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Multicancer Screening market report include:
  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.67 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.72 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 189 Pages
  • Global
From
Colorectal Cancer Screening and Diagnostics Market - Product Image

Colorectal Cancer Screening and Diagnostics Market

  • Report
  • 166 Pages
  • Global
From
Non-Invasive Cancer Diagnostics - Global Strategic Business Report - Product Image

Non-Invasive Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 385 Pages
  • Global
From
Colorectal Cancer Screening & Diagnostic Market by Type, Product, Application, End User - Global Forecast to 2030 - Product Image

Colorectal Cancer Screening & Diagnostic Market by Type, Product, Application, End User - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Next-Generation Breast Cancer Diagnostic & Screening Market by Offerings, Test Type, Stage, Application, End User - Global Forecast to 2030 - Product Image

Next-Generation Breast Cancer Diagnostic & Screening Market by Offerings, Test Type, Stage, Application, End User - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.